A Postauthorization Survey to Document the Therapeutic Management of Oxaliplatin as a First-Line Chemotherapy Regimen in South Africa in Patients with Metastatic Colorectal Cancer
Table 6
Adverse events.
Event
Number (%) of patients
Serious or not
Number (%)
Sensory neuropathy
124 (63.6)
No Yes
122 (62.6) 2 (1.0)
Intermittent neutropenia
58 (29.8)
No Yes
53 (27.2) 5 (2.6)
Intermittent thrombocytopenia
30 (15.4)
No Yes
30 (15.4) —
Intermittent anemia
39 (20.0)
No Yes
36 (18.5) 3 (1.5)
Intermittent nausea
76 (39.0)
No Yes
71 (36.4) 5 (2.6)
Intermittent diarrhoea
78 (40.0)
No Yes
66 (33.8) 12 (6.2)
Intermittent vomiting
29 (14.9)
No Yes
23 (11.8) 6 (3.1)
Stomatitis
28 (14.4)
No Yes
28 (14.4) —
Skin urticaria
8 (4.1)
No Yes
8 (4.1) —
Hand-foot syndrome
20 (10.3)
No Yes
20 (10.3) —
Alopecia
13 (6.7)
No Yes
13 (6.7) —
Allergy
10 (5.1)
No Yes
9 (4.6) 1 (0.5)
Thrombosis/phlebitis
3 (1.5)
No Yes
1 (0.5) 2 (1.0)
Neutropenia with fever
2 (1.0)
No Yes
1 (0.5) 1 (0.5)
Infection
20 (10.3)
No Yes
15 (7.7) 5 (2.6)
Percentages were calculated out of the sample size of 195 patients and do not add up to 100% due to multiple reporting.
